Kintara Therapeutics Inc: Tuhura's Lead Candidate, Ifx-2.0, Was Safe and Well Tolerated at Once Weekly Dosing for 3 Weeks
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.